Cost of Revenue Comparison: Gilead Sciences, Inc. vs Jazz Pharmaceuticals plc

Biopharma Giants: Gilead vs Jazz in Cost of Revenue

__timestampGilead Sciences, Inc.Jazz Pharmaceuticals plc
Wednesday, January 1, 20143788000000117418000
Thursday, January 1, 20154006000000102526000
Friday, January 1, 20164261000000105386000
Sunday, January 1, 20174371000000110188000
Monday, January 1, 20184853000000121544000
Tuesday, January 1, 20194675000000127930000
Wednesday, January 1, 20204572000000148917000
Friday, January 1, 20216601000000440760000
Saturday, January 1, 20225657000000540517000
Sunday, January 1, 20236498000000435577000
Monday, January 1, 202428675800000
Loading chart...

Cracking the code

Cost of Revenue: A Tale of Two Biopharma Giants

In the competitive landscape of biopharmaceuticals, Gilead Sciences, Inc. and Jazz Pharmaceuticals plc have showcased distinct trajectories in their cost of revenue over the past decade. From 2014 to 2023, Gilead Sciences has consistently maintained a higher cost of revenue, peaking in 2021 with a staggering 6.6 billion USD. This represents a 74% increase from its 2014 figures. In contrast, Jazz Pharmaceuticals, while significantly smaller in scale, has demonstrated a steady growth, with its cost of revenue increasing by approximately 270% over the same period, reaching its zenith in 2022.

This comparison not only highlights the scale at which Gilead operates but also underscores Jazz's impressive growth trajectory. As the biopharma industry continues to evolve, these financial metrics provide a window into the strategic priorities and operational efficiencies of these two industry leaders.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025